CHLOROMYCETIN (chloramphenicol sodium succinate) by Pfizer is clinical pharmacology chloramphenicol is a broad-spectrum antibiotic originally isolated from streptomyces venezuelae . Approved for surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. First approved in 1959.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
CHLOROMYCETIN (chloramphenicol sodium succinate) is a broad-spectrum bacteriostatic antibiotic originally isolated from Streptomyces venezuelae, approved in 1959. It treats surface ocular infections of the conjunctiva and/or cornea by inhibiting bacterial protein synthesis through interference with amino acid transfer to ribosomes. The drug is administered via injection and demonstrates minimal resistance development in susceptible organisms.
As a legacy injectable antibiotic approaching loss of exclusivity, this product has likely contracted significantly and operates with a minimal commercial team focused on portfolio maintenance rather than growth.
Clinical Pharmacology Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae . It is primarily bacteriostatic and acts by inhibition of protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. It has been…
Worked on CHLOROMYCETIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CHLOROMYCETIN represents a legacy product support role with limited growth or advancement trajectory; candidates should view this as portfolio maintenance experience rather than career-building opportunity. The zero linked job count and LOE-approaching lifecycle indicate organizational resources are minimal and career mobility within the product team is constrained.